Date Time
Cancer emergency rations could provide basis for new treatment
Insight into cancer cells’ own first aid could help the development of a new type of treatment. Johanna Olweus and her team at the UiO (University of Oslo) and the OUS (Oslo University Hospital) are important contributors to this study, which has been published in Nature.
The researcher team at UiO and OUS. From left: Weiwen Yang, Maarja Laos, Johanna Olweus and Morten Milek Nielsen. Photo: Cathrine Knetter Hoel.
Cancers such as malignant melanoma are notoriously difficult to treat. One of the reasons for this is the lack of good therapeutic targets, i.e. specific points for treatment to attack. Such points are ideally properties of the cancer cells that distinguish them from normal cells.
Radiation Boost Lowers Risk of Prostate Cancer Recurrence
January 25, 2021 An additional external-beam radiation dose delivered directly to the tumor can benefit the prospects of men with non-metastatic prostate cancer, without causing additional side effects. The risk of relapse within five years for these men is smaller than for men who did not receive this boost, as shown by a large-scale study initiated by UMC Utrecht in collaboration with the Netherlands Cancer Institute, UZ Leuven and Radboudumc.
Radiation therapy is one of the treatment options for men with non-metastatic prostate cancer. Physicians deliver the external beam radiation to the entire prostate, as cancer cells often occur in several areas throughout the prostate. Only the main tumor is visible on a scan. If the cancer returns, it often recurs right where that visible tumor was located. Delivering an additional dose to this area appears very effective, as shown by the FLAME trial: a large-scale study involvi
(1)
Renowned immunologist and T cell engineering expert awarded distinguished prize for conducting fundamental translational research of substantial significance for medicine
Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced that the company s co-founder, Board member and Chairman of its Scientific Advisory Board, Ton Schumacher, Ph.D., has been awarded the 2021 Jeantet-Collen Prize for Translational Medicine. Awarded each year by the Louis-Jeantet Foundation to leading-edge researchers who are active in the member states of the Council of Europe, the prize is intended to foster scientific excellence and encourage the continuation of innovative research projects.
Although only a proportion of DCIS cases will progress into invasive cancer, the treatments available for DCIS are similar to treatments for invasive breast cancers.<br />
Updated:
December 29, 2020 18:00 IST
Apart from new findings on coronavirus every single day, the year was also filled with stories from outer space, archeology and anatomy
Share Article
AAA
Apart from new findings on coronavirus every single day, the year was also filled with stories from outer space, archeology and anatomy
The year 2020 also termed as the year of the pandemic, social distancing, work from home, was also the year of research at breakneck speed. Virologists, immunologists, computational biologists, epidemiologists, and medical professionals across the globe turned into superheroes without capes.
Quick sequencing of the whole genome of the novel coronavirus (SARS-CoV-2) helped develop various test kits. We now have not one or two, but multiple COVID-19 vaccines that have succeeded in human clinical trials. Moderna s and Pfizer-BioNTech’s vaccines that use messenger RNA have reported efficacy of about 95%, and the United Kingdom, the United States and the Unit